1. Home
  2. NOMD vs GLUE Comparison

NOMD vs GLUE Comparison

Compare NOMD & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nomad Foods Limited

NOMD

Nomad Foods Limited

HOLD

Current Price

$10.34

Market Cap

1.4B

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$17.60

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOMD
GLUE
Founded
2014
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
NOMD
GLUE
Price
$10.34
$17.60
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$12.50
$32.00
AVG Volume (30 Days)
1.5M
681.1K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
7.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$123,672,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.45
$2.45
P/E Ratio
$8.38
$72.42
Revenue Growth
N/A
63.54
52 Week Low
$8.99
$3.84
52 Week High
$18.33
$25.77

Technical Indicators

Market Signals
Indicator
NOMD
GLUE
Relative Strength Index (RSI) 60.33 40.81
Support Level $9.47 $17.36
Resistance Level $10.46 $18.15
Average True Range (ATR) 0.40 0.98
MACD 0.10 -0.30
Stochastic Oscillator 86.89 4.43

Price Performance

Historical Comparison
NOMD
GLUE

About NOMD Nomad Foods Limited

Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: